Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas

By afschroeder • June 12, 2025

Harrington KJ, Champiat S, Brody JD, Cho BC, Romano E, Golan T, Hyngstrom JR, Strauss J, Oh DY, Popovtzer A, Gomez-Roca C, Perets R, Kim SB, Wong DJ, Powell SF, Khilnani A, Jemielita T, Zhao Q, Zhao R, Ingham M. Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Jun 11. doi: 10.1158/1078-0432.CCR-24-3630. Epub ahead of print. PMID: 40499147.

Tags: Hematology/Oncology, Publications

Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair

Hollowed J, Woo H, Hamburg S, Ardehali A. Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair. Tex Heart Inst J. 2025 Jul[...]

Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease

Fine SA, Lim SY, Siena NM, de Jesus AB, Goh T, Markus L, Russell TA, Kendal JK, Lofftus SY, Shehata MS, Dao HB, Lee A,[...]

Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint Inhibitors: Adrenal Insufficiency Is Not Always the Culprit

Shabsovich D, Kathuria-Prakash N, Zhang J, Cabral M, Lopez L, Sumal A, Drakaki A. Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint[...]